Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) insider Jason R. Kelly sold 143,807 shares of the stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $1.75, for a total value of $251,662.25. Following the transaction, the insider now owns 15,359,782 shares in the company, valued at $26,879,618.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Ginkgo Bioworks Price Performance
DNA stock opened at $1.81 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $1.45 and a 1 year high of $6.38. The firm has a market cap of $3.51 billion, a P/E ratio of -0.79 and a beta of 0.68. The stock has a 50-day simple moving average of $1.80 and a 200-day simple moving average of $2.51.
Ginkgo Bioworks (NYSE:DNA – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Ginkgo Bioworks had a negative net margin of 668.49% and a negative return on equity of 85.90%. The company had revenue of $66.40 million during the quarter, compared to analyst estimates of $54.28 million. On average, equities analysts predict that Ginkgo Bioworks Holdings, Inc. will post -1.41 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Ginkgo Bioworks
Analysts Set New Price Targets
Several research firms recently weighed in on DNA. Morgan Stanley began coverage on Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 target price on the stock. Raymond James cut their price objective on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday, November 22nd. Berenberg Bank assumed coverage on Ginkgo Bioworks in a report on Monday, November 28th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, BTIG Research cut their price objective on Ginkgo Bioworks to $4.00 in a report on Thursday, November 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus target price of $5.92.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.